Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azd-8055. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR known ✓ | P42345 | 20/20 | 1.00 |
| ▸ | FECH | P22830 | 1/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 1/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | RICTOR | Q6R327 | 1/20 | 1.00 |
| ▸ | RPTOR | Q8N122 | 1/20 | 1.00 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 1.00 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-8055 SCHEMBL2929203 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL7861478 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL29388315 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL1219191 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL19263472 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL24264610 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL7861464 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL298416 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL4409051 | 0.96 | MTOR (0.92) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL4408875 | 0.96 | MTOR (0.92) | MTORFECHPIK3R1PIK3CAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4605376-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-08-27 | — | — | EP | claimed |
| CN-120202190-A | Isoquinoline derivatives as protein degrading agents, E7 degrading agents, antiviral agents, tumor therapeutic agents and immunosuppressants | RDP制药股份公司 | 2025-06-24 | — | — | CN | claimed |
| EP-4548977-A2 | NOVEL ISOQUINOLINES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-05-07 | — | — | EP | claimed |
| WO-2024083802-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | VALDOSPAN GMBH (AT) | 2024-04-25 | — | — | WO | claimed |
| EP-4322949-A1 | ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS | RDP Pharma AG (CH) | 2024-02-21 | — | — | EP | claimed |
| CN-117377474-A | Isoquinoline derivatives as antiviral and antitumor agents | RDP制药股份公司 | 2024-01-09 | — | — | CN | claimed |
| WO-2022219157-A1 | ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS | VALDOSPAN GMBH (AT) | 2022-10-20 | — | — | WO | claimed |
| EP-4640238-A1 | THERAPEUTIC AGENT FOR PULMONARY DISEASE, HEPATIC DISEASE OR RENAL DISEASE, WHICH CONTAINS PGAM-CHK1 BINDING INHIBITOR | Kyoto University (JP) | 2025-10-29 | — | — | EP | disclosed |
| EP-4605376-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-08-27 | — | — | EP | disclosed |
| CN-120202190-A | Isoquinoline derivatives as protein degrading agents, E7 degrading agents, antiviral agents, tumor therapeutic agents and immunosuppressants | RDP制药股份公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-119999692-A | Application of AZD8055 compound in improving activity of crop seeds | 广州澄智澜生科技有限公司 | 2025-05-16 | — | — | CN | disclosed |
| EP-4548977-A2 | NOVEL ISOQUINOLINES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-05-07 | — | — | EP | disclosed |
| CN-119912448-A | AZD8055 derivative based on N-methyl-2-hydroxy ethylamine and application thereof | 广州澄智澜生科技有限公司 | 2025-05-02 | — | — | CN | disclosed |
| WO-2022219157-A1 | ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS | VALDOSPAN GMBH (AT) | 2022-10-20 | — | — | WO | disclosed |
| US-20220168316-A1 | METHODS AND COMPOSITIONS FOR TREATING UREA CYCLE DISORDERS | CAMP4 THERAPEUTICS CORPORATION | 2022-06-02 | — | — | US | disclosed |
| US-11298343-B2 | Method for treating thalassemia | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2022-04-12 | — | — | US | disclosed |
| CN-114302746-A | Combination therapy comprising an anti-CD 25 antibody drug conjugate and another agent | ADC治疗有限公司 | 2022-04-08 | — | — | CN | disclosed |
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION | 2022-04-07 | — | — | US | disclosed |
| US-11266655-B2 | Methods and compositions for treating urea cycle disorders | CAMP4 THERAPEUTICS CORPORATION (US) | 2022-03-08 | — | — | US | disclosed |
| CN-108676882-B | Application of NOP14 gene and protein thereof as marker of sensitivity of tumor to mTOR inhibitor | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2022-02-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | PNPLA2, LIPC, PNLIP | MTOR 3881/4885FECH 1388/4885PIK3R1 3386/4885 |
| US-11298343-B2 | Method for treating thalassemia | ULK1, HBZ, ULK2 | MTOR 963/4885FECH 536/4885PIK3R1 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.